GH Research PLC

Stage 3 · Topping · week 4

As of Oct 22, 2026, GH Research is in Stage 3, the topping phase, now in week 4 (since Oct 1, 2026). It closed at $18.50, 39.6% below its 52-week high and below its 200-day average, which is rising.

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. More about the company

$18.50

-2.17% today

$1.3B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is GHRS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S2 17w

S2 16w

S2 23w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 2w → S3 7w → S4 17w → S1 8w → S2 17w → S3 8w → S4 9w → S1 12w → S2 7w → S3 6w → S2 16w → S3 5w → S2 9w → S3 1w → S2 12w → S3 2w → S2 23w → S3 3w current

Total tracked: 165 weeks across 18 stage runs.

GHRS among Biotechnology101st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…101	GHRSGH Research PLC	Stage 3 · wk 4	84	−28.7%

vs 52W High

-39.6%

$12.49 lo$30.64 hi

39.6% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 4

1w13w26w

Week 4, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-13.7%

200 DMA: $21.43 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

1.20x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-28.7%

-32.2%

-1.6%

YTD

+39.7%

+45.0%

Scan Membership

Breakout Watch

Latest: 2025-06-02

4 appearances in last 60 days. First seen: 2023-06-22.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 4 · Vol 1.20x

2026-10-21S3

Wk 3 · Vol 1.23x

2026-10-20S3

Wk 3 · Vol 0.99x

2026-10-19S3

Wk 3 · Vol 1.15x

2026-10-16S3

Wk 3 · Vol 0.57x

2026-10-15S3

Wk 3 · Vol 0.97x

2026-10-14S3

Wk 2 · Vol 1.04x

2026-10-13S3

Wk 2 · Vol 1.47x

2026-10-12S3

Wk 2 · Vol 0.80x

2026-10-09S3

Wk 2 · Vol 0.50x

2026-10-08S3

Wk 2 · Vol 1.14x

2026-10-07S3

Wk 1 · Vol 1.06x

Moving averages & range

50 DMA

$25.17

200 DMA

$21.43

52W High

$30.64

52W Low

$12.49

5D Low

$18.15

Resistance levels (recent highs)

20d High

$24.67

60d High

$30.64

120d High

$30.64

250d High

$30.64

Next resistance

+33.4%

to 20d High

ROE

-18.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.5

GH Research: quick answers

What stage is GH Research in?

As of Oct 22, 2026, GH Research (GHRS) is in Stage 3, the topping phase. It entered Stage 3 on Oct 1, 2026 and is in week 4. What the four stages mean

Is GH Research in an uptrend?

Its uptrend has stalled. GH Research is in Stage 3, the topping phase that follows an advance. It trades 13.7% below its 200-day average, which is rising.

How far is GH Research from its 52-week high?

GH Research closed at $18.50 on Oct 22, 2026, 39.6% below its 52-week high of $30.64. Its 52-week low is $12.49.

How has GH Research performed over the past year?

As of Oct 22, 2026, GH Research is up 45.0% over the past year and up 39.7% so far in 2026.

Which sector and industry is GH Research in?

GH Research is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.